RANDAL J KIRK
CIK 1091823 · Executive Chairman · last filed 2026-03-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.64M
Companies
12
Total Filings
232
Lifetime Open-Market Net
$457.19M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PGEN | Director | 477,492 | $5.45 | $2.60M | $42.06M | 40 | 2026-03-16 |
| AQB | 10%+ Owner | 375 | $0.92 | $345 | $714.5K | 11 | 2021-11-24 |
| PRECIGEN, INC. (XON) Delisted | Executive Chairman | 176,628 | — | — | $206.60M | 80 | 2020-01-07 |
| Theriva Biologics, Inc. (SYN) Delisted | 10%+ Owner | 234,493 | $1.02 | $239.2K | $20.80M | 4 | 2019-04-03 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Director | 3,601,994 | $0.87 | $3.12M | $43.29M | 20 | 2018-10-09 |
| PRPO | 10%+ Owner | 1,689 | $21.85 | $36.9K | -$10.1K | 3 | 2018-08-30 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | 10%+ Owner | 3,917,041 | — | — | $39.79M | 39 | 2018-08-28 |
| Fibrocell Science, Inc. (FCSC) Delisted | 10%+ Owner | 426,719 | — | — | $41.32M | 4 | 2017-03-10 |
| OGEN | 10%+ Owner | 805 | $0.50 | $400 | $8.55M | 3 | 2016-07-05 |
| Precipio, Inc. (TBIO) Delisted | 10%+ Owner | 5,593 | $0.00 | $1 | $4.47M | 5 | 2016-01-11 |
| CLINICAL DATA INC (CLDA) Delisted | Director | 0 | — | — | $49.60M | 10 | 2011-04-12 |
| NEW RIVER PHARMACEUTICALS INC (NRPH) Delisted | Chairman, President and CEO | — | — | — | $0 | 1 | 2007-01-31 |
Recent Filings · Page 18 of 24
232 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-06-08 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Other (J) | −19,214,704 | $0 | EDGAR |
| 2015-05-08 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | +13,175 | $0 | EDGAR |
| 2015-01-27 | PRECIGEN, INC. (XON) Delisted | Buy (P) | +555,556 | $15.00M | EDGAR |
| 2015-01-05 | PRECIGEN, INC. (XON) Delisted | Other (J) | −1,335,320 | $0 | EDGAR |
| 2015-01-05 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Grant (A) | +16,707 | $0 | EDGAR |
| 2014-03-31 | PRECIGEN, INC. (XON) Delisted | Buy (P) | +243,001 | $6.25M | EDGAR |
| 2014-03-07 | Precipio, Inc. (TBIO) Delisted | Buy (P) | — | $0 | EDGAR |
| 2013-12-26 | OGEN | Conv (C) | +1,396,482 | $3.94M | EDGAR |
| 2013-12-19 | Theriva Biologics, Inc. (SYN) Delisted | Buy (P) | +5,000,000 | $5.00M | EDGAR |
| 2013-11-22 | OGEN | Buy (P) | +2,484,980 | $6.21M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.